Form 4: Health Catalyst Chief People Officer Sells Shares Under 10b5-1 Trading Plan

Linda Llewelyn, Chief People Officer of Health Catalyst, sold 1,365 shares of common stock at $8.50 per share on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Linda Llewelyn, the Chief People Officer of Health Catalyst, sold 1,365 shares of the company's common stock on November 15, 2024.
• The sale was executed at a price of $8.50 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2024.
• Following the transaction, Ms. Llewelyn directly owns 112,910 shares of Health Catalyst common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies like Health Catalyst, similar to practices at companies such as Oracle, Salesforce, and Workday.
• These plans allow insiders to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company, which is typical for routine insider sales.

Stakeholder Impact

• The sale of shares by a company officer may have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Health Catalyst, insider trading, Form 4, stock sale, 10b5-1 plan, Linda Llewelyn, HCAT, Chief People Officer